CA 19-9 as a Predictor for Response and Survival in Advanced Pancreatic Cancer Patients Treated With Chemoradiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 73, Issue 4, 2009, Pages 1148-1154

  Koom, Woong Sub ^a   Seong, Jinsil ^a   Kim, Yong Bae ^a   Pyun, Hae Ok ^a   Song, Si Young ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

CA 19 9; Chemoradiotherapy; Pancreatic cancer; Survival; Tumor response

Indexed keywords

CARBOHYDRATES; PATIENT MONITORING;

CA 19-9; CHEMORADIOTHERAPY; PANCREATIC CANCER; SURVIVAL; TUMOR RESPONSE;

TUMORS;

CA 19-9 ANTIGEN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; DEMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT INFORMATION; PATIENT SELECTION; PREDICTION AND FORECASTING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LOCALIZATION;

ADULT; AGED; ANALYSIS OF VARIANCE; CA-19-9 ANTIGEN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 61349202170     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.06.1483     Document Type: Article

References (34)

1. Koprowski H., Steplewski Z., Mitchell K., et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 5 (1979) 957-971
2. Del Villano B.C., Brennan S., Brock P., et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem 29 (1983) 549-552
3. Ducreux M., Boige V., and Malka D. CA 19-9 and pancreatic carcinoma, a revival?. Onkologie 30 (2007) 12-13
4. Goonetilleke K.S., and Siriwardena A.K. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33 (2007) 266-270
5. Rhodes J.M. Usefulness of novel tumour markers. Ann Oncol 10 Suppl. 4 (1999) 118-121
6. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 85 (1990) 350-355
7. Ferrone C.R., Finkelstein D.M., Thayer S.P., et al. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 24 (2006) 2897-2902
8. Gogas H., Lofts F.J., Evans T.R., et al. Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas?. Br J Cancer 77 (1998) 325-328
9. Halm U., Schumann T., Schiefke I., et al. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 82 (2000) 1013-1016
10. Montgomery R.C., Hoffman J.P., Riley L.B., et al. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol 4 (1997) 551-556
11. Ohara K., Tatsuzaki H., Molotkova N.G., et al. Utility of serum CA 19-9 monitoring in preoperative radiotherapy for pancreatic cancer. Hepatogastroenterology 48 (2001) 859-863
12. Okusaka T., Okada S., Sato T., et al. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer. Hepatogastroenterology 45 (1998) 867-872
13. Abrams R.A., Grochow L.B., Chakravarthy A., et al. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: Survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int J Radiat Oncol Biol Phys 44 (1999) 1039-1046
14. Katz A., Hanlon A., Lanciano R., et al. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys 41 (1998) 393-396
15. Micke O., Bruns F., Kurowski R., et al. Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys 57 (2003) 90-97
16. Micke O., Bruns F., Schafer U., et al. CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer Res 23 (2003) 835-840
17. Willett C.G., Daly W.J., and Warshaw A.L. CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg 172 (1996) 350-352
18. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
19. Karachristos A., Scarmeas N., and Hoffman J.P. CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg 9 (2005) 1286-1292
20. Ishii H., Okada S., Sato T., et al. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 44 (1997) 279-283
21. Ko A.H., Hwang J., Venook A.P., et al. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 93 (2005) 195-199
22. Rocha Lima C.M., Savarese D., Bruckner H., et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 20 (2002) 1182-1191
23. Stemmler J., Stieber P., Szymala A.M., et al. Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?. Onkologie 26 (2003) 462-467
24. Ziske C., Schlie C., Gorschluter M., et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 89 (2003) 1413-1417
25. Brambs H.J., and Claussen C.D. Pancreatic and ampullary carcinoma. Ultrasound, computed tomography, magnetic resonance imaging and angiography. Endoscopy 25 (1993) 58-68
26. Rothenberg M.L., Abbruzzese J.L., Moore M., et al. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer 78 (1996) 627-632
27. Bang S., Chung H.W., Park S.W., et al. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 40 (2006) 923-929
28. Maisey N.R., Norman A.R., Hill A., et al. CA19-9 as a prognostic factor in inoperable pancreatic cancer: The implication for clinical trials. Br J Cancer 93 (2005) 740-743
29. Saad E.D., Machado M.C., Wajsbrot D., et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer 32 (2002) 35-41
30. Ikeda M., Okada S., Tokuuye K., et al. Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 91 (2001) 490-495
31. Ker C.G., Chen J.S., Lee K.T., et al. Assessment of serum and bile levels of CA19-9 and CA125 in cholangitis and bile duct carcinoma. J Gastroenterol Hepatol 6 (1991) 505-508
32. Kim H.J., Kim M.H., Myung S.J., et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: Analysis using a receiver operating characteristic curve. Am J Gastroenterol 94 (1999) 1941-1946
33. Mann D.V., Edwards R., Ho S., et al. Elevated tumour marker CA19-9: Clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 26 (2000) 474-479
34. Patel A.H., Harnois D.M., Klee G.G., et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 95 (2000) 204-207